• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Curis Inc.

    11/14/25 4:30:04 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CRIS alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 4)


    Curis, Inc.

    (Name of Issuer)


    Common Stock, par value $0.01 per share

    (Title of Class of Securities)


    231269309

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    231269309


    1Names of Reporting Persons

    Maverick Capital, Ltd.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    TEXAS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    49,554.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    49,554.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    49,554.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.4 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP No.
    231269309


    1Names of Reporting Persons

    Maverick Capital Management, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    TEXAS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    49,554.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    49,554.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    49,554.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.4 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    231269309


    1Names of Reporting Persons

    Lee S. Ainslie III
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    49,554.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    49,554.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    49,554.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.4 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Curis, Inc.
    (b)Address of issuer's principal executive offices:

    128 Spring Street, Building C - Suite 500, Lexington, MA 02421
    Item 2. 
    (a)Name of person filing:

    This Schedule 13G (the "Schedule 13G") is being filed on behalf of each of the following persons (each, a "Reporting Person"): Maverick Capital, Ltd. ("Maverick"); Maverick Capital Management, LLC ("Maverick Capital Management"); and Lee S. Ainslie III ("Mr. Ainslie"). This Schedule 13G relates to Common Stock (as defined herein) held for the accounts of Maverick's clients.
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of (i) Maverick and Maverick Capital Management is 1900 N. Pearl Street, 20th Floor, Dallas, Texas 75201, and (ii) Mr. Ainslie is 360 South Rosemary Ave., Suite 1440, West Palm Beach, Florida 33401.
    (c)Citizenship:

    Maverick is a Texas limited partnership; Maverick Capital Management is a Texas limited liability company; and Mr. Ainslie is a United States citizen.
    (d)Title of class of securities:

    Common Stock, par value $0.01 per share
    (e)CUSIP No.:

    231269309
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Ownership as of September 30, 2025, is incorporated by reference to items (5) - (9) and (11) of the cover pages of the Reporting Persons. The ownership percentages are based on 12,928,853 outstanding shares of Common Stock, par value $0.01 per share ("the Common Stock") of Curis, Inc. ("the Issuer"), as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 6, 2025, and assume the exercise of warrants held by the Reporting Persons for an aggregate of 49,554 shares of Common Stock. Maverick is the investment advisor of (i) Maverick Fund USA, Ltd, a Texas limited partnership, which holds warrants exercisable for 6,167 shares of Common Stock, (ii) Maverick Fund II, Ltd., a Cayman exempt corporation, which holds warrants exercisable for 7,869 shares of Common Stock, (iii) Maverick Long Enhanced Fund, Ltd, a Cayman exempt corporation, which holds warrants exercisable for 18,697 shares of Common Stock, (iv) Maverick HP, L.P., a Delaware limited partnership, which holds warrants exercisable for 9,768 shares of Common Stock, and (v) Maverick Long Fund, Ltd., a Cayman exempt corporation, which holds warrants exercisable for 7,053 shares of Common Stock. Maverick is an investment adviser registered under Section 203 of the Investment Advisers Act of 1940 and, as such, may be deemed to have beneficial ownership of the Common Stock which are the subject of this filing through the investment discretion it exercises over its clients' accounts. Maverick Capital Management is the General Partner of Maverick. Mr. Ainslie is the manager of Maverick Capital Management and the Managing Partner of Maverick.
    (b)Percent of class:

    Maverick: 0.4% Maverick Capital Management: 0.4% Mr. Ainslie: 0.4%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Maverick: 0 Maverick Capital Management: 0 Mr. Ainslie: 0

     (ii) Shared power to vote or to direct the vote:

    Maverick: 49,554 Maverick Capital Management: 49,554 Mr. Ainslie: 49,554

     (iii) Sole power to dispose or to direct the disposition of:

    Maverick: 0 Maverick Capital Management: 0 Mr. Ainslie: 0

     (iv) Shared power to dispose or to direct the disposition of:

    Maverick: 49,554 Maverick Capital Management: 49,554 Mr. Ainslie: 49,554

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Maverick Capital, Ltd.
     
    Signature:/s/ Trevor Wiessmann*
    Name/Title:By: Maverick Capital Management, LLC, its General Partner By: Lee S. Ainslie III, Manager
    Date:11/14/2025
     
    Maverick Capital Management, LLC
     
    Signature:/s/ Trevor Wiessmann*
    Name/Title:Lee S. Ainslie III, Manager
    Date:11/14/2025
     
    Lee S. Ainslie III
     
    Signature:/s/ Trevor Wiessmann*
    Name/Title:Lee S. Ainslie III
    Date:11/14/2025

    Comments accompanying signature:  *Under Power of Attorney, dated March 15, 2018
    Get the next $CRIS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRIS

    DatePrice TargetRatingAnalyst
    5/19/2025$17.00Buy
    H.C. Wainwright
    11/17/2023$26.00Buy
    Truist
    4/4/2022Outperform → Mkt Perform
    Raymond James
    10/13/2021$15.00Outperform
    Raymond James
    More analyst ratings

    $CRIS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by President & CEO Dentzer James E

    4 - CURIS INC (0001108205) (Issuer)

    5/22/25 4:13:54 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Hohneker John

    4 - CURIS INC (0001108205) (Issuer)

    5/22/25 4:13:41 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Greenacre Martyn D

    4 - CURIS INC (0001108205) (Issuer)

    5/22/25 4:13:30 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRIS
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Curis Inc.

    SCHEDULE 13G/A - CURIS INC (0001108205) (Subject)

    11/14/25 4:30:04 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: Curis Inc. filed SEC Form 8-K: Financial Statements and Exhibits

    8-K/A - CURIS INC (0001108205) (Filer)

    11/13/25 5:16:00 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 filed by Curis Inc.

    S-8 - CURIS INC (0001108205) (Filer)

    11/6/25 4:27:20 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRIS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Curis to Present at Upcoming 30th Annual SNO Meeting

    LEXINGTON, Mass., Nov. 14, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that Curis will report emavusertib and BTKi clinical data in Primary CNS Lymphoma (PCNSL) and Secondary CNS Lymphoma (SCNSL) in three presentations and preclinical data on emavusertib in an oral presentation at the 30th Annual Meeting of the Society for Neuro-Oncology (SNO) on November 19-23: November 21, 2025 – 4:30 PM ET (11:30 AM HT) Format:      Poster Pre

    11/14/25 9:26:00 AM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Curis Provides Third Quarter 2025 Business Update

    Management to host conference call and webcast today at 4:30 p.m. ET LEXINGTON, Mass., Nov. 6, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today reported its financial and operating results for the third quarter ended September 30, 2025. "We made good progress advancing our clinical studies in PCNSL, CLL, and AML this quarter. We continue to enroll PCNSL patients in the TakeAim Lymphoma study in both the BTKi-experienced and BTKi-naïve

    11/6/25 4:00:00 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Curis to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on November 6, 2025

    LEXINGTON, Mass., Oct. 30, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its third quarter 2025 financial and operating results on Thursday, November 6, 2025, at 4:00 p.m. ET. Management will host a conference call and simultaneous webcast on the same day at 4:30 p.m. ET. Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast

    10/30/25 4:00:00 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRIS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Curis with a new price target

    H.C. Wainwright resumed coverage of Curis with a rating of Buy and set a new price target of $17.00

    5/19/25 8:52:11 AM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Truist initiated coverage on Curis with a new price target

    Truist initiated coverage of Curis with a rating of Buy and set a new price target of $26.00

    11/17/23 7:37:50 AM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Curis downgraded by Raymond James

    Raymond James downgraded Curis from Outperform to Mkt Perform

    4/4/22 11:27:43 AM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRIS
    Leadership Updates

    Live Leadership Updates

    View All

    Curis Adds Three New Executives to Management Team Strengthening Medical Affairs, Clinical Development and Clinical Operations

    LEXINGTON, Mass., Jan. 3, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the appointment of three new executives to its management team. Joining the company, are Felix Geissler, M.D., Ph.D., as Vice President of Medical Affairs, Kimberly Steinmann, M.D., as Vice President of Clinical Development, and Dora Ferrari, as Vice President of Clinical Operations. They will be reporting directly to Dr. Reinhard von Roemeling, Senior Vice President, Clinical Devel

    1/3/22 8:00:00 AM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Curis Appoints John A. Hohneker, M.D. To Board Of Directors

    LEXINGTON, Mass., Dec. 6, 2021  /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the appointment of John A. Hohneker, M.D. to its Board of Directors. Dr. Hohneker brings 30 years of drug development and leadership experience within the biotech and pharmaceutical industries.  He most recently served as President and CEO of Anokion SA. Prior to Anokion, he was President of Research and Development at FORMA Therapeutics Inc., where he guided the company's transitio

    12/6/21 8:00:00 AM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    LEXINGTON, Mass., Jan. 8, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on January 4, 2021, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 185,000 shares of Curis common stock to three new employees, with a grant date of January 4, 2021 (the "Q1 2021 Inducement Grants"). Each of the Q1 2021 Inducement Grants has an exercise price per share equal to the closing price of the Company's common stock on January 4, 2021. Each stock option has a 10 year term and vests ov

    1/8/21 4:01:00 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRIS
    Financials

    Live finance-specific insights

    View All

    Curis to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on November 6, 2025

    LEXINGTON, Mass., Oct. 30, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its third quarter 2025 financial and operating results on Thursday, November 6, 2025, at 4:00 p.m. ET. Management will host a conference call and simultaneous webcast on the same day at 4:30 p.m. ET. Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast

    10/30/25 4:00:00 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Curis to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2025

    LEXINGTON, Mass., July 29, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its second quarter 2025 financial and operating results on Tuesday, August 5, 2025, at 8:00 a.m. ET. Management will host a conference call and simultaneous webcast on the same day at 8:30 a.m. ET. Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast c

    7/29/25 8:30:00 AM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Curis to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on May 6, 2025

    LEXINGTON, Mass., April 29, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its first quarter 2025 financial and operating results on Tuesday, May 6, 2025, at 8:00 a.m. ET. Management will host a conference call and simultaneous webcast on the same day at 8:30 a.m. ET. Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast can

    4/29/25 8:00:00 AM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRIS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Curis Inc.

    SC 13G/A - CURIS INC (0001108205) (Subject)

    11/13/24 2:05:06 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Curis Inc.

    SC 13G - CURIS INC (0001108205) (Subject)

    11/1/24 4:35:37 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Curis Inc.

    SC 13G - CURIS INC (0001108205) (Subject)

    4/15/24 2:12:19 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care